The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Revance Therapeutics's share price is $3.0275.
Revance Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $2.69. Hence, Revance Therapeutics's PS Ratio for today is 1.13.
The historical rank and industry rank for Revance Therapeutics's PS Ratio or its related term are showing as below:
RVNC'
s PS Ratio Range Over the Past 10 Years
Min: 0.93 Med: 340.63 Max: 6460
Current: 1.13
During the past 13 years, Revance Therapeutics's highest PS Ratio was 6460.00. The lowest was 0.93. And the median was 340.63.
RVNC's PS Ratio is ranked better than 92.52% of 1016
companies
in the Biotechnology industry
Industry Median: 8.76
vs RVNC: 1.13
Revance Therapeutics Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Revance Therapeutics was 9.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 118.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 160.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 72.60% per year.
During the past 13 years, Revance Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 467.00% per year. The lowest was -50.70% per year. And the median was 50.80% per year.
Back to Basics: PS Ratio
Revance Therapeutics PS Ratio Historical Data
The historical data trend for Revance Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Revance Therapeutics's PS Ratio
For the Biotechnology subindustry, Revance Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revance Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's PS Ratio falls into.
Revance Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Revance Therapeutics's Share Price of today is $3.0275. Revance Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Revance Therapeutics (NAS:RVNC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Revance Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of Revance Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVNC has been successfully added to your 